A naukri.com initiative
Bioengineer
7d
332
Image Credit: Bioengineer
Dual Immunotherapy Enhances Progression-Free Survival in Advanced Squamous Cell Skin Cancer: Findings from the Alliance Trial
- A phase II clinical trial led by the Alliance for Clinical Trials in Oncology demonstrated that combining avelumab and cetuximab significantly enhances progression-free survival in advanced cutaneous squamous cell carcinoma (cSCC).
- Advanced cSCC poses clinical challenges with limited effective options after initial treatments fail, leading to an estimated annual death toll of 2,000 to 8,000 individuals.
- Immune checkpoint inhibitors like cemiplimab and pembrolizumab have improved outcomes in advanced cSCC, but some patients still experience progression, prompting the Alliance trial to investigate avelumab and cetuximab combination therapy.
- The combination leverages complementary mechanisms of avelumab (anti-PD-L1) and cetuximab (anti-EGFR), potentially overcoming resistance mechanisms in advanced cSCC.
- Results from the study showed a substantial improvement in median progression-free survival with the dual therapy, with a hazard ratio of 0.48 indicating a 52% reduction in the risk of disease progression or death.
- The combination therapy also demonstrated a favorable trend in overall survival, but statistical significance was not reached due to limited events and sample size.
- Side effects were more frequent with avelumab plus cetuximab, with rash and infusion-related reactions being the predominant serious adverse events, but manageable with medical intervention.
- The trial validates the concept that targeting both adaptive and innate immune pathways can enhance tumor control, showcasing a promising avenue for the treatment of advanced cSCC.
- This collaborative study between the Alliance for Clinical Trials in Oncology and EMD Serono demonstrates the importance of public-private partnerships in advancing cancer therapeutics.
- The findings open doors for further research on combination immunotherapies in cSCC and other squamous cell malignancies, emphasizing the future of personalized and mechanistically informed cancer care.
Read Full Article
20 Likes
For uninterrupted reading, download the app